NewswireToday - /newswire/ -
Palo Alto, CA, United States, 2006/11/21 - New analysis from Frost & Sullivan, U.S. Drug Discovery Contract Research Organization Markets, reveals that the market earned revenues of $7.44 billion in 2006 and is likely to reach $19.35 billion in 2013..
The contract research organization (CRO) market presents a mix of numerous challenges and opportunities and is likely to provide pharmaceutical and biotechnology market participants the opportunity to achieve their strategic objectives by offering services that seek to reduce cost and time-to-market drug candidates. CROs are likely to capitalize on this tremendous opportunity by pursuing a mix of organic and inorganic growth initiatives that will ensure greater penetration of the market and higher share of R&D spending.
New analysis from Frost & Sullivan, U.S. Drug Discovery Contract Research Organization Markets, reveals that the market earned revenues of $7.44 billion in 2006 and is likely to reach $19.35 billion in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Drug Discovery Contract Research Organization Markets, then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
Biotechnology and pharmaceutical companies are outsourcing their R&D to CROs due to the lack of internal expertise, infrastructure, mounting costs of drug development, and stringent regulatory guidelines. Biotechnology companies have limited investments in development infrastructure compared to their pharmaceutical counterparts. This is resulting in greater business volumes for CROs from the biotechnology market.
“The increase in globalization of trials is likely to result in several CROs expanding across geographical boundaries and augmenting their capacity to cater to this opportunity,” notes Frost & Sullivan Research Analyst Barath Shankar S. “As the market continues to enlarge and inorganic growth emerges as a critical component of this expansion, the trend of deepening focus on core expertise is becoming crucial.”
Along with offering required expertise to manage complex global trials across a variety of therapeutic segments, CROs provide a full line of preclinical and clinical services, which aid rapid expansion of the drug discovery CRO market. Their ability to deliver clinical trial participants with high levels of efficiency and productivity are further strengthening the need for companies to outsource R&D.
Several leading CROs have proactively established global presence through a strategic mix of organic and inorganic growth strategies. Achieving the right breadth and depth of services can prominently position these CROs in the highly competitive and rapidly growing market.
Market participants can gain prominence by shifting from the traditional route of drug discovery to the emerging "proof of concept" model. The complexity of the drug discovery process necessitates high degree of technical change to drive innovation and achieve greater efficiency in commercially launching products.
“However, there is an increasing level of commoditization of CRO services due to similarity in quality and range of services provided,” observes Shankar. “CROs can benefit from offering cost-effective services to retain companies likely to change loyalties based on lower cost benefit.”
The U.S. Drug Discovery Contract Research Organization Markets is part of the Pharmaceuticals and Biotechnology subscription, which also includes research in the following markets: global pharmaceutical contract manufacturing, analysis of top 10 specialty pharmaceutical companies, and global vaccines. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Analyst interviews are available to the press.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.